AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.190
-0.001 (-0.58%)
At close: Dec 20, 2024, 4:00 PM
0.198
+0.008 (4.21%)
After-hours: Dec 20, 2024, 7:59 PM EST
AIM ImmunoTech Employees
As of December 31, 2023, AIM ImmunoTech had 28 total employees, including 26 full-time and 2 part-time employees. The number of employees increased by 4 or 16.67% compared to the previous year.
Employees
28
Change (1Y)
4
Growth (1Y)
16.67%
Revenue / Employee
$6,786
Profits / Employee
-$854,607
Market Cap
12.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Zhongchao | 142 |
| STRATA Skin Sciences | 99 |
| Sol-Gel Technologies | 36 |
| Imunon | 33 |
| Brainstorm Cell Therapeutics | 29 |
| Eterna Therapeutics | 8 |
| Immuron | 7 |
| Evoke Pharma | 4 |
AIM News
- 4 days ago - AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - GlobeNewsWire
- 4 days ago - AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting - Business Wire
- 5 days ago - AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card - Business Wire
- 7 days ago - Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board - GlobeNewsWire
- 9 days ago - AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members - Business Wire
- 9 days ago - AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue - GlobeNewsWire
- 9 days ago - Kellner Group Announces Support from Another Former AIM Senior Executive - GlobeNewsWire
- 10 days ago - AIM's Clinical Strategy Under Incumbent Board Has Totally Failed - GlobeNewsWire